Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. Read more about Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Read more about Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial cancer surgery. Read more about The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial cancer surgery.
Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. Read more about Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
Effect of frailty on postoperative readmissions and cost of care for ovarian cancer. Read more about Effect of frailty on postoperative readmissions and cost of care for ovarian cancer.
Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer. Read more about Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer.
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. Read more about Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study.
An integrated molecular profile of endometrioid ovarian cancer. Read more about An integrated molecular profile of endometrioid ovarian cancer.
Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 508-5 Read more about Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 508-5
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An N Read more about A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An N
